The lipid formulations of amphotericin B

Bibliography

• BARCHIESI F, COLOMBO AL, MCGOUGH DA, RINALDI MG: Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. .1. Clin. Microbiol (1994) 32(10):2494–2500.
   Google Scholar
• FRANZOT SP, HAMDAN JS: In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob. Agents Chemother. (1996) 40(3):822–824.
   PubMedGoogle Scholar
• PFALLER MA, MESSER S, JONES RN: Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother: (1997) 41(2):233–235.
   PubMedGoogle Scholar
• ROTOWA NA, SHADOMY HJ, SHADOMY S: In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses (1990) 33(4):203–211.
   PubMed Web of Science ®Google Scholar
• ABI-SAID D, ANASSIE EJ: New emerging fungal pathogens. Baillieres Clin. Infect. Dis. (1995) 2(1):71–87.
   Google Scholar
• WALSH TJ, MELCHER GP, RINALDI MG et al.: Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. Clin. Microbial. (1990) 28(7):1616–1622.
   PubMed Web of Science ®Google Scholar
• BOLARD J: How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta (1986) 864(3-4):257–304.
   PubMed Web of Science ®Google Scholar
• VERTUT-CROQUIN A, BOLARD J, GARY-BOBO CM: Transfer of amphotericin B from gel state vesicles to mycoplasma cells: biphasic action on potassium transport and permeability. Antimicrob. Agents Chemother. (1985) 28(2):167–171.
   PubMedGoogle Scholar
• SURARIT R, SHEPHERD MG: The effects of azole and polyene antifungals on the plasma membrane enzymes of Candida albicans. J. Med. Vet. Myra]. (1987) 25(6):403–413.
   PubMedGoogle Scholar
• CAILLOT D, RENY G, CASASNOVAS 0, CHAVANET P, BONOTTE B: A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. Antimicrob. Chemother: (1994) 33(3):603–613.
   Google Scholar
• CHAVANET P, GARRY I, CHARLIER N, CAILLOT D, KISTERMAN JP, D'ATHIS M: Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br. Med. J. (1992) 305(6859):921–925.
   PubMedGoogle Scholar
• SCHOFFSKI P, FREUND M, WUNDER R et al.: Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Br. Med. J. (1998) 317(7155):379–384.
   PubMedGoogle Scholar
• •Amphotericin B diluted in intralipid was associated with severe pulmonary toxicity.
   Google Scholar
• JOLY V, AUBRY P, NDAYIRAGIDE A et al.: Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. (1996) 23(3):556–562.
   PubMedGoogle Scholar
• BARRETT JP, VARDULAKI KA, CONLON C et al.: A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Then (2003) 25(5):1295–1321.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis of the safety and efficacy of lipid formulations of amphotericin B compared to conventional amphotericin B showing a reduction in overall mortality.
   Google Scholar
• FIELDING RM, SINGER AW, WANG LH, BABBAR S, GUO LS: Relationship of pharmacolkinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. (1992) 36(2)299–307.
   Google Scholar
• JANKNEGT R, DE MARIE S, BAKKER-WOUDENBERG IA, CROMMELIN DJ: Liposomal and lipid formulations of amphotericin B. Clinical pharmacolkinetics. Clin. Pharmacokinet. (1992) 23(4):279–291.
   PubMed Web of Science ®Google Scholar
• SANDERS SW, BUCHI KN, GODDARD MS, LANG JK, TOLMAN KG: Single-dose pharmacolkinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. (1991) 35(6):1029–1034.
   PubMed Web of Science ®Google Scholar
• STEVENS DA: Overview of amphotericin B colloidal dispersion (Amphocil). Infect. (1994) 28\(Suppl. 1):45–49.
   Google Scholar
• HERBRECHT R, LETSCHER V, ANDRES E, CAVALIER A: Safety and efficacy of amphotericin B colloidal dispersion. An overview. Chemotherapy (1999) 45\(Suppl. 1):67–76.
   Google Scholar
• HERBRECHT R, LETS CHER-BRUV, BOWDEN RA et al.: Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Ear. J. Clin. Microbial. Infect. Dis (2001) 20(7):460–466.
   PubMed Web of Science ®Google Scholar
• •A case series suggesting the utility of lipid formulations of amphotericin B and surgery in treating zygomycete infections.
   Google Scholar
• WHITE MH, ANAISSIE EJ, KUSNE S et al.: Amphotericin B colloidal dispersion versus amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. (1997) 24(4):635–642.
   PubMedGoogle Scholar
• BOWDEN R, CHANDRASEKAR P, WHITE MH et al: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis (2002) 35(4):359–366.
   PubMed Web of Science ®Google Scholar
• ••The only large randomized trial comparinga lipid formulation of amphotericin B and Amphotericin B in invasive aspergillosis.
   Google Scholar
• WHITE MH, BOWDEN RA, SANDLER ES et al.: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. (1998) 27(2):296–302.
   PubMed Web of Science ®Google Scholar
• •A demonstration in a double blind study of the high frequency of infusion-related events following therapy with ABCD.
   Google Scholar
• HERBRECHT R: Safety of amphotericin B colloidal dispersion. Ear. Clin. Microbial. Infect. Dis. (1997) 16(1):74–80.
   PubMedGoogle Scholar
• BOWDEN RA, CAYS M, GODLEY T, MAMELOK RD, VAN BURIKJA: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J. Infect. Dis. (1996) 173(5):1208–1215.
   PubMed Web of Science ®Google Scholar
• TIMMERS GJ, ZWEEGMAN S, SIMOONS-SMIT AM, VAN LOENEN AC, TOUW D, HUIJGENS PC: Amphotericin B colloidal dispersion (Amphocil) versus fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant. (2000) 25(8):879–884.
   PubMed Web of Science ®Google Scholar
• GURWITH M, MAMELOK R, PIETRELLI L, DU MC: Renal sparing by amphotericin B colloidal dispersion: clinical experience in 572 patients. Chemotherapy (1999) 45\(Suppl. 1):39–47.
   Google Scholar
• HERBRECHT R, ANDRES E, LETSCHER V et al.: Treatment with high cumulative doses of amphotericin B colloidal dispersion. Efficacy and tolerance in 96 patients. Blood (1996) 88\(Suppl. 1):502a.
   Google Scholar
• JANOFF AS, BONI LT, POPESCU MC et al.: Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. U. S. A (1988) 85(16):6122–6126.
   PubMedGoogle Scholar
• OLSEN SJ, SWERDEL MR, BLUE B, CLARK JM, BONNER DP: Tissue distribution of amphotericin B lipid complex in laboratory animals. Pharm. Pharmacol (1991) 43(12):831–835.
   PubMedGoogle Scholar
• CLARK JM, WHITNEY RR, OLSEN SJ et al.: Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother: (1991) 35(4):615–621.
   PubMed Web of Science ®Google Scholar
• DIX SP, WINGARD JR: Amphotericin B lipid complex: review of safety, pharmacolkinetics and efficacity. Drugs (1996) 32(Suppl. G):19–25.
   Google Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27(3):603–618.
   PubMed Web of Science ®Google Scholar
• SWENSON CE, PERKINS WR, ROBERTS P et al: In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob. Agents Chemother. (1998) 42(4):767–771.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, HIEMENZ JW, SEIBEL NL et al.: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. (1998) 26(6):1383–1396.
   PubMed Web of Science ®Google Scholar
• WINGARD JR: Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. (1997) 19(4):343–347.
   PubMed Web of Science ®Google Scholar
• ANAISSIE EJ, WHITE M, UZUN 0 et al.: Amphotericin B lipid complex versus amphotericin B for the treatment of hematogenous and invasive candidiasis: a prospective randomized multicenter trial. Proceedings of the 351 Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA (1995).
   Google Scholar
• ••A randomised, comparative trial of ABLCand amphotericin B in invasive candidiasis. Unfortunately this abstract never turned into a publication.
   Google Scholar
• SHARKEY PK, GRAYBILL JR, JOHNSON ES et al.: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1996) 22(2):315–321.
   PubMed Web of Science ®Google Scholar
• LISTER J: Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur. Haematol (1996) 57(Suppl.):18–23.
   Google Scholar
• HERBRECHT R, AUVRIGNON A, ANDRES E et al: Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur. Clin. Microbiol Infect. Dis. (2001) 20(2):77–82.
   PubMedGoogle Scholar
• HAY RJ: Liposomal amphotericin B, AmBisome. Infect. (1994) 28\(Suppl. 1):35–43.
   Google Scholar
• DE MARIE S, JANKNEGT R, BAKKER-WOUDENBERG IA: Clinical use of liposomal and lipid-complexed amphotericin B. j Antimicrob. Chemother: (1994) 33(5):907–916.
   PubMedGoogle Scholar
• ADLER-MOORE J: AmBisome targeting to fungal infections. Bone Marrow Transplant. (1994) 14\(Suppl. 5):S3–S7.
   Google Scholar
• PROFFITT RT, SATORIUS A, CHIANG SM, SULLIVAN L, ADLER-MOORE JP: Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Antimicrob. Chemother. (1991) 28(Suppl. B):49–61.
   Google Scholar
• TOLLEMAR J, RINGDEN 0, TYDEN G: Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients: efficacy and safety evaluation. Clin. Transplant. (1990) 4(3):167–175.
   Google Scholar
• RINGDEN 0, MEUNIER F, TOLLEMAR J et al.: Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Antimicrob. Chemothec (1991) 28(Suppl. B):73–82.
   Google Scholar
• PRENTICE HG, HANN IM, HERBRECHT R et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol (1997) 98(3):711–718.
   PubMed Web of Science ®Google Scholar
• •Comparative study showing a better tolerance of liposomal amphotericin B in the empirical therapy of febrile neutropenia and suggesting an improved efficacy.
   Google Scholar
• WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl. I Med. (1999) 340(10):764–771.
   Google Scholar
• ••A large, doubl-blind, randomised studythat demonstrated the superiority of liposomal amphotericin B over amphotericin B in the empirical therapy of suspected fungal infections in neutropenic patients.
   Google Scholar
• WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl. .1. Med. (2002) 346(4):225–234.
   Google Scholar
• ••This study failed to demonstrate non-inferiority of voriconazole compared to liposomal amphotericin B in the empirical therapy of febrile neutropenia and underlines the difficulties of choosing the appropriate end points.
   Google Scholar
• FISCHER T, HEUSSEL G, HUBER C: Liposomal amphotericin B for fever and neutropenia. N Engl. I Med. (1999) 341(15):1152–1155.
   PubMedGoogle Scholar
• JOHNSON LB, KAUFFMAN CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis (2003) 36(5):630–637.
   PubMed Web of Science ®Google Scholar
• WINGARD JR, WHITE MH, ANAISSIE E, RAFFALLI J, GOODMAN J, ARRIETA A: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis (2000) 31(5):1155–1163.
   PubMed Web of Science ®Google Scholar
• ••A head-to-head comparison of liposomalamphotericin B and ABLC demonstrating the differences in tolerance between the two agents.
   Google Scholar
• LEENDERS AC, DAENEN S, JANSEN RL et al.: Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. .1. Haematol (1998) 103(1):205–212.
   Google Scholar
• •An underpowered study suggesting an increased efficacy of liposomal amphotericin B over amphotericin B in documented fungal infections.
   Google Scholar
• LEENDERS AC, REISS P, PORTEGIES P et al.: Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS (1997) 11(12):1463–1471.
   PubMed Web of Science ®Google Scholar
• ELLIS M, SPENCE D, DE PAUW B et al: An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. (1998) 27(6):1406–1412.
   PubMed Web of Science ®Google Scholar
• •Provides a demonstration that liposomal amphotericin B is effective in first-line therapy of invasive aspergillosis.
   Google Scholar
• TOLLEMAR J, HOCKERSTEDT K, ERICZON BG, JALANKO H, RINGDEN 0: Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation (1995) 59(1):45–50.
   Google Scholar
• TOLLEMAR J, RINGDEN 0, ANDERSSON S et al.: Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant. Proc. (1993) 25(1 Pt 2):1495–1497.
   Google Scholar
• KELSEY SM, GOLDMAN JM, MCCANN S et al: Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo- controlled study. Bone Marrow Transplant. (1999) 23(2):163–168.
   PubMedGoogle Scholar
• TOLLEMAR J, RINGDEN 0, ANDERSSON S, SUNDBERG B, LJUNGMAN P, TYDEN G: Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. (1993) 12(6):577–582.
   PubMedGoogle Scholar
• TOLLEMAR J, HOCKERSTEDT K, ERICZON BG, JALANKO H, RINGDEN 0: Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Transplant. Proc. (1995) 27(1):1195–1198.
   PubMedGoogle Scholar
• DAVIDSON RN, DI MARTINO L, GRADONI L et al: Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. (1996) 22(6):938–943.
   PubMed Web of Science ®Google Scholar
• MEYERHOFF A: US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. (1999) 28(1):42–48.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, GOODMAN JL, PAPPAS P et al.: Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother: (2001) 45(12):3487–3496.
   PubMed Web of Science ®Google Scholar
• ••Provides a demonstration that higher dosesof liposomal amphotericin B can be administered safely.
   Google Scholar
• LUKE RG, BOYLE JA: Renal effects of amphotericin B lipid complex. Am. Kidney Dis. (1998) 31(5):780–785.
   PubMed Web of Science ®Google Scholar
• TIPHINE M, LETSCHER-BRU V, HERBRECHT R: Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect. Dis. (1999) 1(4):273–283.
   PubMedGoogle Scholar
• GALLAGHER JC, DODDS ASHLEY ES,DREW RH, PERFECT JR: Antifungal pharmacotherapy for invasive mould infections. Expert. Opin. Pharmacether: (2003) 4(2):147–164.
   PubMed Web of Science ®Google Scholar
• •An extensive review of the current therapeutic strategies for mould infections.
   Google Scholar
• CAGNONI PJ, WALSH TJ, PRENDERGAST MM et al.: Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. .1. Clin. Once]. (2000) 18(12):2476–2483
   Google Scholar
• ••The only pharmacoeconomic analysis ofliposomal amphotericin B use in the empirical treatment of febrile neutropenia. This analysis is based on the trial reported in [48].
   Google Scholar